Preoperative chemotherapy for esophageal cancer based, on chemosensitivity testing

Okuma, Toshitada; Yoshioka, Masakazu; Isechi, Susumu; Kondo, Keiichiro; Tabira, Yoichi; Torigoe, Yoshitsugu; Miyauchi, Yoshimasa

doi:10.1016/s0022-5223(94)70179-2

Cited by 7 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34 Significant regression of the primary tumor and metastatic lesions may cause down‐staging, allowing surgical therapy to be more curative. Esophageal cancers have been effectively managed using neoadjuvant chemotherapy 6 –12 . 34 In our hospital the effect of neoadjuvant chemotherapy using chemosensitivity testing for patients with esophageal cancer is under prospective investigation 11 .…”

Section: Discussionmentioning

confidence: 99%

“…34 In our hospital the effect of neoadjuvant chemotherapy using chemosensitivity testing for patients with esophageal cancer is under prospective investigation 11 . 12 However, we need biologic markers unaffected by neoadjuvant chemotherapy for use as prognostic indicators. p27 and cyclin A were determined to be significant markers, especially p27, which was independent in both groups.…”

Section: Discussionmentioning

confidence: 99%

“…The dosage and schedule of administration for each drug were as described previously. 11,12 Immunohistochemistry Tissue samples were ®xed in 10% formalin and embedded in paran. Two or three representative blocks that included the greatest depth of tumor were selected and sectioned for subsequent immunostaining.…”

Section: Methodsmentioning

confidence: 99%

“…Since 1989, in vitro chemosensivity testing has improved survival 11 . 12 However, neoadjuvant chemotherapy does not always yield a good outcome. The concept of tumor cell individuality is derived from the observation that the same drug is not equally effective in all patients with the same disease, histopathologic characteristics and stage 13 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The prognostic significance of cell cycle markers in esophageal cancer after neoadjuvant chemotherapy

Yasunaga¹,

Tabira²,

Kondo³

et al. 1999

Diseases of the Esophagus

View full text Add to dashboard Cite

Proliferating cell nuclear antigen (PCNA), p27 and cyclin A were analyzed by immunohistochemistry in 89 patients (untreated control n = 40, neoadjuvant chemotherapy n = 49) with esophageal cancer invading the submucosal lesion. The mitotic index (MI) was calculated as the percentage of mitotic cells. In control subjects, the mean PCNA, p27, cyclin A and MI were, respectively, 60.4%, 18.0%, 19.9% and 1.7%; in the chemotherapy group, these values were 46.8%, 15.1%, 18.0% and 1.2% respectively. Neoadjuvant chemotherapy decreased PCNA and the MI significantly. As prognostic indicators, PCNA and the MI were significant in control subjects and p27 and cyclin A were significant in the chemotherapy group. Using multivariate analysis, p27 was a prognostic factor in both groups and cyclin A was prognostic only in the chemotherapy group. Although PCNA and the MI were useful growth and prognostic markers in untreated control subjects, their significance was lost after neoadjuvant chemotherapy. p27 and cyclin A were determined to be significant markers in the neoadjuvant chemotherapy group, especially p27, which was independent in both groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The prognostic significance of cell cycle markers in esophageal cancer after neoadjuvant chemotherapy

Yasunaga¹,

Tabira²,

Kondo³

et al. 1999

Diseases of the Esophagus

View full text Add to dashboard Cite

show abstract

“…However, since the majority of patients with esophageal cancer tend to have widespread disease at the time of detection, esophageal cancer still remains one of the most difficult neoplasms to be controlled by surgery alone [4]. As a result, both radiotherapy and chemotherapy have been applied to the patients with advanced esophageal cancer at many institutes in order to obtain either a preoperative downstaging of the primary tumor or to control the disease conservatively [5][6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer

et al. 1998

View full text Add to dashboard Cite

Background and Objectives: Hyperthermochemoradiotherapy (HCR) has been performed on numerous patients with esophageal cancer. The purpose of this study is to demonstrate the recent advances in HCR. Methods: From 1965 to 1997, 294 patients given preoperative chemoradiotherapy (CR) or HCR were classified according to the anticancer agent that was administered (CR; group A given bleomycin (BLM); group B given cis-diamminedichloroplatinum (II) (CDDP), HCR; group C given BLM; and Group D given CDDP). The local response and the long-term results were investigated. Results: The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4%) in group A, 22 (73.3%) in group B, 79 (63.7%) in group C, and 36 (73.5%) in group D. A significant difference was observed between groups A and B (P < 0.05). The highest incidence of markedly effective cases was observed in group D. The 5-year survival rates for the group A and B patients were 17.2% and 43.9%, respectively (P < 0.01), while the same rates for those of groups C and D were 25.6% and 57.8%, respectively (P < 0.05). Our results thus showed CDDP to have a greater effect than BLM, while HCR had a greater effect than CR. Conclusions: Preoperative HCR has improved thanks to recent advances in anticancer agents.

show abstract

Neoadjuvant chemotherapy with cisplatinum/5-fluorouracil/low-dose leucovorin for advanced squamous cell carcinoma of the esophagus

Ide

Nakamura

Hayashi

et al. 1997

Semin. Surg. Oncol.

View full text Add to dashboard Cite

Preoperative chemotherapy for esophageal cancer based, on chemosensitivity testing

Cited by 7 publications

References 14 publications

The prognostic significance of cell cycle markers in esophageal cancer after neoadjuvant chemotherapy

The prognostic significance of cell cycle markers in esophageal cancer after neoadjuvant chemotherapy

Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer

Neoadjuvant chemotherapy with cisplatinum/5-fluorouracil/low-dose leucovorin for advanced squamous cell carcinoma of the esophagus

Contact Info

Product

Resources

About